An investigation of cortical thickness and antidepressant response in major depressive disorder: a CAN-BIND study report

Publication date: Available online 13 January 2020Source: NeuroImage: ClinicalAuthor(s): Jee Su Suh, Luciano Minuzzi, Pradeep Reddy Raamana, Andrew Davis, Geoffrey B. Hall, Jacqueline Harris, Stefanie Hassel, Mojdeh Zamyadi, Stephen R. Arnott, Gésine L. Alders, Roberto B. Sassi, Roumen Milev, Raymond W. Lam, Glenda M. MacQueen, Stephen C. Strother, Sidney H. Kennedy, Benicio N. FreyAbstractMajor depressive disorder (MDD) is considered a highly heterogeneous clinical and neurobiological mental disorder. We employed a novel layered treatment design to investigate whether cortical thickness features at baseline differentiated treatment responders from non-responders after 8 and 16 weeks of a standardized sequential antidepressant treatment. Secondary analyses examined baseline differences between MDD and controls as a replication analysis and longitudinal changes in thickness after 8 weeks of escitalopram treatment. 181 MDD and 95 healthy comparison (HC) participants were studied. After 8 weeks of escitalopram treatment (10-20mg/d, flexible dosage), responders (>50% decrease in Montgomery-Åsberg Depression Scale score) were continued on escitalopram; non-responders received adjunctive aripiprazole (2-10mg/d, flexible dosage). MDD participants were classified into subgroups according to their response profiles at weeks 8 and 16. Baseline group differences in cortical thickness were analyzed with FreeSurfer between HC and MDD subgroups as well as between response groups. Two-sta...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research